Eileen Wrabel

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “896 Characterizing macrophage heterogeneity in HR+/HER2- metastatic breast cancer reveals novel mechanisms of resistance”.

896 Characterizing macrophage heterogeneity in HR+/HER2- metastatic breast cancer reveals novel mechanisms of resistance

Regular and Young Investigator Award Abstracts(2023)10.1136/jitc-2023-sitc2023.0896

N/A

0DataRank · unranked

0 citations

Kenichi Shimada, Madeline G Townsend, Tianyu Li, Nabihah Tayob, Molly DiLullo +9 more

Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2024-010430

N/A

0DataRank · unranked

14 citations

Noah Graham, Lestat R. Ali, Christina I. Herold, Jennifer Desrosiers, Khanh Do +13 more

Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer

Nature Communications(2025)10.1038/s41467-025-66659-y

N/A

0DataRank · unranked

2 citations

Adrienne G. Waks, Erica Pimenta, Breanna Titchen, Kevin Bi, Sabrina Y. Camp +16 more